MMRF follow-up

This was posted last night at the MMRF iHub board.  Intriguing spin on this company and suggesting some inherent value heretofore overlooked:

MMRF why it could be trading for dollars seriously. Now Biotech is not my thing....so here's a biotech for dummies like me version

MMRF merged into FVRL, got these worthless drugs left in FVRL.
Remember FVRL used to be a big NASDAQ stock, raised 100's of millions for their promising cancer drugs. They failed a late phase 3 trial. The problem is their cancer drug wasn't being absorbed into the cancer to do it's curative thing.

The FVRL drug failed because the cancer cells wouldn't absorb FVRL's medicine. They cure the cancer but the drug bounces off the cancer before it gets absorbed and kills the cancer.

Some guy recently comes up with a binding agent let's call it cancer drug super glue. This super glue now allows FVRL's medicine to actually stick to the cancer cells. Not just stick, but actually become absorbed. Remember if their drug gets absorbed into the cells it can kill the cancer. Now the medicine doesn't just bounce off the cancer it gets soaked in and starts curing the cancer. Who the F knew that would happen. Someone invented a drug crazy glue that works on the drugs MMRF got from FVRL they thought were worthless. Now they might be worth billions.

Read this carefully

It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance.

rituximab doesn't stick to many cancers, FVRL's drug could stick now with the new crazy glue someone invented. So now all that $140 million dollars worth of FVRL test data they thought was junk because their drug woudln't stick to the Cancer cells has to be looked at again in light of now it could stick because of the new crazy glue someone invented. That's why this stock could go to many, many dollars by taking over a big chunk of rituximabs $5.6 billion in sales and is why the China drug guys want in.

I beleive they will license the various biotech assets to larger Pharma/biotech companies. These larger companies would pay MMRF licensing fee's, milestone payments and a percentage of future sales while covering all expenses along the way. Don't for one second expect MMRF to self fund these drug trials.

We got the first sign of one of these licensing deals with this news. Expecting to see several more deals like this one going forward.

MMR: MMR Info Systems And Sanofi-Aventis Enter Into Agreement Regarding Anti-CD20 Monoclonal